$AZN has released its latest earnings report, showcasing robust growth and developments. Total revenue surged 21% year-over-year, with a core EPS increase of 19%. While the company reported potential risks in China, ongoing investigations could impact their operations. Highlights include steady growth across various therapy areas and expectations of continued innovation. ⚕️💰 Investors should note the evolving market conditions while anticipating future opportunities. For detailed insights, visit valueverge.com/AZN.